RESUMO
Fewer than 30 cases of Mycobacterium senegalense infection have been reported. We report a complicated case of M. senegalense infection in Memphis, Tennessee, in the southeastern United States. The patient's comorbidities of past organ transplant and insulin-dependent diabetes required delicate consideration of those health conditions to guide treatment.
Assuntos
Diabetes Mellitus , Transplante de Rim , Infecções por Mycobacterium não Tuberculosas , Infecções por Mycobacterium , Mycobacterium , Humanos , Mycobacterium/genética , Tennessee/epidemiologia , Transplante de Rim/efeitos adversos , Infecções por Mycobacterium/diagnóstico , Infecções por Mycobacterium/tratamento farmacológico , Infecções por Mycobacterium/etiologia , Infecções por Mycobacterium não Tuberculosas/diagnóstico , Infecções por Mycobacterium não Tuberculosas/tratamento farmacológico , Infecções por Mycobacterium não Tuberculosas/microbiologiaRESUMO
INTRODUCTION: Dermatologic manifestations of diseases in solid organ transplant recipients are common due to long-term immunosuppression. CASE PRESENTATION: We present the case of a 63-year-old man with a kidney transplant who exhibited subcutaneous nodules on lower extremities, cytopenia, and asymptomatic pulmonary infiltrate. Through a skin biopsy and 16S ribosomal RNA (rRNA) sequencing, Mycobacterium haemophilum was identified. His clinical course was complicated by empyema, septic arthritis, and recurrence of his skin manifestations, despite ongoing antimicrobial treatment. DISCUSSION: This case emphasizes the challenges and potential complications associated with M haemophilum infections in solid organ transplant recipients receiving long-term immunosuppressive therapy. It highlights the importance of employing advanced diagnostic techniques when evaluating dermatologic manifestations in these patients. The patient's complex clinical course also underscores the difficulties involved in effectively addressing and managing complications that may arise even after initiating therapy.
Assuntos
Transplante de Rim , Mycobacterium haemophilum , Humanos , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Mycobacterium haemophilum/isolamento & purificação , Infecções por Mycobacterium/diagnóstico , Infecções por Mycobacterium/microbiologia , Infecções por Mycobacterium/tratamento farmacológico , Hospedeiro ImunocomprometidoRESUMO
Tuberculosis (TB) is a significant global health threat, and cases of infection with non-tuberculous mycobacteria (NTM) causing lung disease (NTM-LD) are rising. Bacteriophages and their gene products have garnered interest as potential therapeutic options for bacterial infections. Here, we have compiled information on bacteriophages and their products that can kill Mycobacterium tuberculosis or NTM. We summarize the mechanisms whereby viable phages can access macrophage-resident bacteria and not elicit immune responses, review methodologies of pharmaceutical product development containing mycobacteriophages and their gene products, mainly lysins, in the context of drug regulatory requirements and we discuss industrially relevant methods for producing pharmaceutical products comprising mycobacteriophages, emphasizing delivery of mycobacteriophages to the lungs. We conclude with an outline of some recent case studies on mycobacteriophage therapy.
Assuntos
Micobacteriófagos , Humanos , Animais , Tuberculose/tratamento farmacológico , Mycobacterium tuberculosis , Terapia por Fagos/métodos , Infecções por Mycobacterium não Tuberculosas/tratamento farmacológico , Infecções por Mycobacterium não Tuberculosas/terapia , Infecções por Mycobacterium/terapia , Infecções por Mycobacterium/tratamento farmacológicoRESUMO
Mendelian susceptibility to mycobacterial disease (MSMD) is caused by approximately 21 genetic defects, including a mutation in Interferon-Gamma Receptor 1 (IFNGR1). IFNGR1 deficiency leads to a loss of cellular responsiveness to type II Interferon (IFN-γ), which plays a significant role in controlling intracellular bacteria. This study explored the response of IFN-ß therapy in a patient with partial IFNGR1 deficiency to treat invasive mycobacterial infection. The biological therapy was used successfully as an adjuvant to anti-mycobacterial medications to treat a 17-year-old girl with partial IFNGR1 deficiency who presented with a recurrent mycobacterial infection that extended to her central nervous system, which resulted in clinical and radiological improvement. This report suggests that activation of type I IFN through Signal Transducers and Activators of Transcription1 (STAT1) could bypass the early IFN-γ signaling defects and activate IFN-γ production. For that reason, IFN-ß might be used as a beneficial adjuvant therapy for managing extensive central nervous system mycobacterial infection, especially in patients with IFNGR1 deficiency.
Assuntos
Receptor de Interferon gama , Interferon beta , Infecções por Mycobacterium , Receptores de Interferon , Humanos , Feminino , Adolescente , Receptores de Interferon/deficiência , Receptores de Interferon/genética , Interferon beta/uso terapêutico , Infecções por Mycobacterium/tratamento farmacológico , Resultado do Tratamento , Interferon gama/genética , Fator de Transcrição STAT1/genética , Fator de Transcrição STAT1/metabolismoRESUMO
BACKGROUND: The incidence of pediatric inflammatory bowel disease is increasing. tumor necrosis factor alpha inhibitors medicines improved the prognosis of affected subjects. Nonetheless, a proportion of patients do not respond or lose response to treatment. Newer biologics, like ustekinumab, have been approved for adults. The pediatric off-label use of these drugs is increasing, despite limited safety evidence. We report a case of disseminated mycobacterial infection (MI) presenting with reactive polyarthritis (Poncet's disease, PD) in a girl with Crohn's disease receiving various immunosuppressants, including ustekinumab. CASE REPORT: A 12-year-old girl with Crohn's disease was admitted for acute-onset migratory polyarthritis of large and small joints and opioid-resistant pain. She had recently received adalimumab and methotrexate and was currently under treatment with ustekinumab. She was vaccinated with Bacillus Calmette-Guérin and screened for tuberculosis before starting immunosuppressants. Interferon-gamma release assay, Mantoux test and chest computed tomography scan were negative. Disseminated MI with PD was diagnosed following positive cultures for Mycobacterium tuberculosis complex in blood and intestinal biopsies (with negative in synovial fluid and gastric aspirate). Whole-exome sequencing did not identify any genetic susceptibility to MI. Antituberculosis treatment eradicated MI. CONCLUSIONS: Children with inflammatory bowel disease receiving combination immunosuppressive treatments including tumor necrosis factor alpha inhibitors and anti-IL-12/23 agents are at higher risk for MI. Disseminated MI should be considered and ruled out in these patients when presenting with pulmonary, extrapulmonary or unusual clinical manifestations, like PD. The collection of multiple specimens (including intestinal biopsies) for mycobacterial culture is recommended when mycobacterial disease is suspected.
Assuntos
Doença de Crohn , Imunossupressores , Ustekinumab , Humanos , Feminino , Doença de Crohn/tratamento farmacológico , Doença de Crohn/complicações , Criança , Ustekinumab/uso terapêutico , Ustekinumab/efeitos adversos , Imunossupressores/uso terapêutico , Imunossupressores/efeitos adversos , Artrite Reativa/tratamento farmacológico , Artrite Reativa/microbiologia , Infecções por Mycobacterium/tratamento farmacológicoRESUMO
Programmed cell death protein 4 (PDCD4) is instrumental in regulating a range of cellular processes such as translation, apoptosis, signal transduction, and inflammatory responses. There is a notable inverse correlation between PDCD4 and the mammalian target of rapamycin (mTOR) pathway, which is integral to cellular growth control. Activation of mTOR is associated with the degradation of PDCD4. Although the role of PDCD4 is well established in oncogenesis and immune response regulation, its function in mycobacterial infections and its interplay with the mTOR pathway necessitate further elucidation. This study investigates the modulation of PDCD4 expression in the context of mycobacterial infections, revealing a consistent pattern of downregulation across diverse mycobacterial species. This observation underscores the potential utility of PDCD4 as a biomarker for assessing mTOR pathway activation during such infections. Building on this finding, we employed a novel approach using PDCD4-based mTOR (Tor)-signal-indicator (TOSI) reporter cells for the high-throughput screening of FDA-approved drugs, focusing on mTOR inhibitors. This methodology facilitated the identification of several agents, inclusive of known mTOR inhibitors, which upregulated PDCD4 expression and concurrently exhibited efficacy in impeding mycobacterial proliferation within macrophages. These results not only reinforce the significance of PDCD4 as a pivotal marker in the understanding of infectious diseases, particularly mycobacterial infections, but also illuminate its potential in the identification of mTOR inhibitors, thereby contributing to the advancement of therapeutic strategies. IMPORTANCE: This study emphasizes the critical role of the mammalian target of rapamycin (mTOR) pathway in macrophage responses to mycobacterial infections, elucidating how mycobacteria activate mTOR, resulting in PDCD4 degradation. The utilization of the (Tor)-signal-indicator (TOSI) vector for real-time monitoring of mTOR activity represents a significant advancement in understanding mTOR regulation during mycobacterial infection. These findings deepen our comprehension of mycobacteria's innate immune mechanisms and introduce PDCD4 as a novel marker for mTOR activity in infectious diseases. Importantly, this research laid the groundwork for high-throughput screening of mTOR inhibitors using FDA-approved drugs, offering the potential for repurposing treatments against mycobacterial infections. The identification of drugs that inhibit mTOR activation opens new avenues for host-directed therapies, marking a significant step forward in combating tuberculosis and other mycobacterial diseases.
Assuntos
Proteínas Reguladoras de Apoptose , Biomarcadores , Infecções por Mycobacterium , Proteínas de Ligação a RNA , Transdução de Sinais , Serina-Treonina Quinases TOR , Serina-Treonina Quinases TOR/metabolismo , Humanos , Proteínas Reguladoras de Apoptose/metabolismo , Proteínas Reguladoras de Apoptose/genética , Proteínas de Ligação a RNA/metabolismo , Proteínas de Ligação a RNA/genética , Infecções por Mycobacterium/microbiologia , Infecções por Mycobacterium/tratamento farmacológico , Infecções por Mycobacterium/metabolismo , Infecções por Mycobacterium/imunologia , Biomarcadores/metabolismo , Macrófagos/microbiologia , Macrófagos/imunologia , Macrófagos/metabolismo , Animais , Camundongos , Mycobacterium/genéticaRESUMO
La tuberculosis y otras micobacteriosis constituyen asociaciones o coinfecciones frecuentes en pacientes con sida y se asocian con una elevada mortalidad. En esta revisión se actualizan los tratamientos de las principales enfermedades micobacterianas asociadas al sida (tuberculosis y micobacteriosis por Mycobacterium avium), con especial énfasis en las interacciones farmacológicas entre antimicobacterianos, principalmente rifampicina y claritromicina, y fármacos antirretrovirales. Se analizan los esquemas de tratamiento, su duración, la quimioprofilaxis primaria y secundaria y el momento óptimo de iniciación del tratamiento antirretroviral. Finalmente se describe el síndrome inflamatorio de reconstitución inmune y su tratamiento.
Assuntos
Humanos , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Antibacterianos/uso terapêutico , Antirretrovirais/uso terapêutico , Infecções por Mycobacterium/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/diagnóstico , Claritromicina/uso terapêutico , Interações Medicamentosas , Infecções por Mycobacterium/diagnóstico , Rifampina/uso terapêutico , Tuberculose/diagnóstico , Tuberculose/tratamento farmacológicoRESUMO
Desde 1989 hasta Julio de 1994 el Laboratorio de Referencia Nacional de Micobacterias procesó cepas de 99 pacientes VIH/SIDA con enfermedades por micobacterias. En 87 se efectuaron las pruebas de tipificación; 73 (83.9 porciento) resultaron M. tuberculosis y 14 (16.1 porciento) M. no tuberculosis, 12 de ellas del complejo MAI. El test de sensibilidad a drogas antituberculosas se realizó en 81 casos, 69 del complejo M. tuberculosis y en los 12 MAI; estos últimos fueron todos resistentes, la mayoría a 5 de las 8 drogas probadas. De los 69 casos de TBC, 42 eran nuevos, vírgenes a tratamiento y en ellos se encontró un 11.9 porciento de resistencia inicial global. Este porcentaje es semejante a las cifras históricas nacionales, determinadas en enfermos VIH (-). Se concluye que la resistencia en estos pacientes no guarda relación con su condición biológica de VIH+/SIDA, sino con su pobre adherencia al tratamiento, por sus condiciones socioculturales
Assuntos
Humanos , Infecções Oportunistas Relacionadas com a AIDS/complicações , Antituberculosos/farmacocinética , Infecções por Mycobacterium/tratamento farmacológico , Mycobacterium/efeitos dos fármacos , Resistência Microbiana a Medicamentos , Infecções por HIV/complicaçõesRESUMO
Presentamos el caso de un niño de occho años que desarrolló una infección del pie despues de un trauma plantar. El estudio bacteriológico demostró la presencia de Mycobacterium chelonei ssp. abscessus en el exudado de la lesión. Se hace una reseña de ña evolución clínica, que finalmente fue satisfactoria después del tatamiento por varias semanas con antimicrobianos y drenajes quirúrgicos. Se hace uma revisión de la literatura para llamar la atención sobre este tipo de infecciones en nuestro medio